as 11-15-2024 4:00pm EST
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Founded: | 1995 | Country: | United States |
Employees: | N/A | City: | LAKE FOREST |
Market Cap: | 105.8M | IPO Year: | 1997 |
Target Price: | $3.19 | AVG Volume (30 days): | 862.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.72 | EPS Growth: | N/A |
52 Week Low/High: | $0.73 - $1.80 | Next Earning Date: | 11-11-2024 |
Revenue: | $125,763,000 | Revenue Growth: | -25.77% |
Revenue Growth (this year): | -18.35% | Revenue Growth (next year): | 4.68% |
ASRT Breaking Stock News: Dive into ASRT Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Thomson Reuters StreetEvents
6 days ago
Associated Press Finance
6 days ago
GlobeNewswire
6 days ago
GlobeNewswire
7 days ago
GuruFocus.com
10 days ago
GlobeNewswire
19 days ago
GlobeNewswire
a month ago
The information presented on this page, "ASRT Assertio Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.